. 2022 Mar 31;14(7):1770. doi: 10.3390/cancers14071770

Table 1.

Main characteristics of the selected studies.

Authors, Ref	Year	Country	N pts	Age Median (Range) or Mean (SD)	Type of Therapy	Tracer	Scanner	Time of PET
Incerti et al. [13]	2015	Italy	68	67 (51–81)	sTomotherapy	[¹¹C]Choline	PET/CT	baseline
Pasqualetti et al. [16]	2020	Italy	51	70 (50–81)	SBRT	[¹⁸F]Choline	PET/CT	baseline
Fodor et al. [9]	2017	Italy	81	68 (51–81)	sTomot herapy	[¹¹C]Choline	PET/CT	baseline
Bouman-Wammes et al. [17]	2017	Netherlands	43	68 (52.6–81.1)	SBRT	[¹⁸F]Choline	PET/CT	baseline
Incerti et al. [15]	2017	Italy	20	67 (51–80)	sTomotherapy	[¹¹C]Choline	PET/CT	baseline
Franzese et al. [18]	2017	Italy	26	71 (56–90)	SBRT	[¹¹C]Choline	PET/CT	baseline and 6 months after therapy
Schlenter et al. [28]	2018	Germany	67	73 (51–83)	IMRT and SIB	[¹⁸F]Choline	PET/CT	baseline
Kalinauskaite et al. [19]	2020	Germany	50	62 (47–75)	SBRT	[⁶⁸Ga]PSMA	PET/CT	baseline and restaging
Hurmuz et al. [20]	2020	Turkey	176	65 (42–84)	SBRT or IMRT	[⁶⁸Ga]PSMA	PET/CT	baseline
Oehus et al. [14]	2020	Germany	78	64 (48–78)	SBRT or RT	[⁶⁸Ga]PSMA	PET/CT	baseline and restaging
Onal et al. [21]	2021	Turkey	74	64 (49–87)	SBRT	[⁶⁸Ga]PSMA	PET/CT	baseline
Bergamin et al. [31]	2020	Australia	25	72 (62–83)	SBRT	[⁶⁸Ga]PSMA	PET/CT	baseline
Henkenberens et al. [22]	2020	Germany	32	63 (53–74)	RT	[⁶⁸Ga]PSMA	PET/CT	baseline
Emmett el al., [10]	2020	Australia	129	68 (IQR 63–72)	IMRT	[⁶⁸Ga]PSMA	PET/CT	baseline
Shakespeare et al. [29]	2019	Australia	46	70 (51–81)	SBRT	[⁶⁸Ga]PSMA	PET/CT	baseline
Narang et al. [30]	2020	India	44	69 (52–84)	SBRT	[⁶⁸Ga]PSMA	PET/CT	baseline
Baumann et al. [23]	2018	Germany	5	71(66–78)	IGRT	[⁶⁸Ga]PSMA	PET/CT	baseline
Artigas et al. [24]	2019	Belgium	20	69 (56–82)	RT	[⁶⁸Ga]PSMA	PET/CT	baseline
Guler et al. [25]	2018	Turkey-Belgium	23	68 (54–78)	IMRT-IGRT	[⁶⁸Ga]PSMA	PET/CT	baseline
Emmett et al. [11]	2017	Australia	164	68 (IQR 62–71)	RT	[⁶⁸Ga]PSMA	PET/CT	baseline
Schmidt-Hegemann et al. [12]	2018	Germany	129	72 (47–83)	RT	[⁶⁸Ga]PSMA	PET/CT	baseline
Henkenberens et al. [26]	2017	Germany	42	66.5 (49–85)	RT	[⁶⁸Ga]PSMA	PET/CT	baseline
Koerber et al. [27]	2021	Germany	86	65 (49–80)	RT	[⁶⁸Ga]PSMA	PET/CT	baseline
Schwarzenböck et al. [33]	2016	Germany	32	70 (52–82)	docetaxel	[¹¹C]Choline	PET/CT	baseline, after the 1st and 10th cyclee
Ceci et al. [35]	2016	Italy	61	67.5 (57–84)	docetaxel	[¹¹C]Choline	PET/CT	Baseline, after 4 or 8 or 12 cycles
Schwarzenböck et al. [34]	2016	Germany	11	68.72 (5.83)	docetaxel + ADT	[¹¹C]Choline	PET/CT	baseline and 7–21 days after therapy
Quaquarini et al. [36]	2019	Italy	29	71 (42–82)	docetaxel	[¹⁸F]Choline	PET/CT	baseline and 14–58 days after therapy
Seitz et al. [37]	2018	Germany	23	75 (54–82)	docetaxel	[⁶⁸Ga]PSMA	PET/CT	Baseline and end of therapy (3 weeks after)
Anton et al. [38]	2020	Australia	25	63	docetaxel + ADT	[⁶⁸Ga]PSMA	PET/CT	baseline and within 6 weeks following upfront docetaxel
Has Simsek et al. [39]	2021	Turkey	52	67 (53–82)	docetaxel	[⁶⁸Ga]PSMA	PET/CT	at least after six cycles of therapy
Caffo et al. [40]	2014	Italy	12	77 (59–86)	enzalutamide	[¹⁸F]Choline	PET/CT	baseline, 3 and 6 months after therapy
Maines et al. [41]	2016	Italy	30	76.9 (59.2–86.7)	enzalutamide	[¹⁸F]Choline	PET/CT	baseline and during therapy
De Giorgi et al. [43]	2014	Italy	43	73 (57–87)	abiraterone	[¹⁸F]Choline	PET/CT	baseline and 3–6 weeks after the start of therapy
De Giorgi et al. [42]	2015	Italy	36	72 (48–90)	enzalutamide	[¹⁸F]Choline	PET/CT	baseline and 3–6 weeks after the start of therapy
Chen et al. [44]	2021	China	45	68 (62–72)	abiraterone	[⁶⁸Ga]PSMA	PET/CT	before and after 6 months post-therapy
Zukotynski et al. [45]	2021	USA	16	71.5 (66.8–72.0)	abiraterone or enzalutamide	[¹⁸F]DCFPyL	PET/CT	at baseline and within 2–4 months after starting therapy.
Plouznikof et al. [46]	2019	Belgium	26	abiraterone 71.9 ± 7.6 enzalutamide 70.4 ± 9.6	abiraterone or enzalutamide	[⁶⁸Ga]PSMA	PET/CT	Baseline and after 110 days (IQR 76–124) for enzalutamide and after 87 days (IQR 71–242) for abiraterone
Filippi et al. [47]	2020	Italy	20	75	[²²³Ra] dichloride	[¹⁸F]Choline	PET/CT	baseline, 1 month after 223Ra
García Vicente et al. [48]	2019	Spain	40	72.55 (±8.58)	[²²³Ra]dichloride	[¹⁸F]Choline	PET/CT	baseline
Ahmadzadehfar et al. [49]	2017	Germany	32	73 (62–84)	[²²³Ra]dichloride	[⁶⁸Ga]PSMA	PET/CT	baseline and 4 weeks after full 223 Ra therapye

Legend: SBRT = stereotactic body radiation therapy; IMRT = intensity-modulated RT; SIB = simultaneous integrated boost; IGRT = image-guided RT; ADT = androgen-deprivation therapy; IQR = interquartile range; DCFPyL = PSMA agent.